Skip to main content
EJNMMI Research

Table 1 Baseline clinical, laboratory, and imaging variables between the two cohorts

From: Phase analysis single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) detects dyssynchrony in myocardial scar and increases specificity of MPI

Variable

Derivation (N = 340)

Validation (N = 138)

p value

Scar, n (%)

105 (31%)

40 (29%)

0.68

Demographics

 Age

67.3 (12.3)

68.3 (12.0)

0.40

 Male gender, n (%)

232 (68%)

98 (71%)

0.55

 Caucasian, n (%)

310 (91%)

126 (91%)

0.96

Past medical history

 Coronary artery disease, n (%)

161 (47%)

64 (46%)

0.85

 STEMI/NSTEMI, n (%)

50 (15%)

18 (13%)

0.64

 Prior PCI, n (%)

96 (28%)

32 (23%)

0.26

 Prior CABG, n (%)

42 (12%)

19 (14%)

0.67

 HFrEF, n (%)

51 (15%)

23 (17%)

0.65

 HFpEF, n (%)

7 (2%)

5 (4%)

0.32

 ICD, n (%)

10 (3%)

1 (1%)

0.14

 CRT, n (%)

1 (0%)

0 (0%)

0.52

 Pacemaker, n (%)

12 (4%)

4 (3%)

0.73

 Hypertension, n (%)

215 (63%)

86 (62%)

0.85

 Hyperlipidemia, n (%)

236 (69%)

86 (62%)

0.13

 Smoking, n (%)

167 (48%)

57 (42%)

0.33

 OSA, n (%)

65 (19%)

34 (25%)

0.18

 COPD, n (%)

21 (6%)

6 (4%)

0.43

 Diabetes, insulin dependent, n (%)

27 (8%)

7 (5%)

0.27

 Dialysis, n (%)

6 (2%)

1 (1%)

0.39

 Peripheral vascular disease

41 (12%)

16 (12%)

0.89

 Atrial fibrillation/atrial flutter, n (%)

57 (17%)

33 (24%)

0.07

 Ventricular tachycardia, n (%)

6 (2%)

4 (3%)

0.43

 Family history of premature CAD, n (%)

46 (14%)

14 (10%)

0.31

 Valve disease (moderate or greater), n (%)

28 (14%)

10 (11%)

0.50

Medications

 Aspirin, n (%)

211 (62%)

96 (70%)

0.12

 Beta-blocker, n (%)

187 (55%)

75 (54%)

0.90

 Ticagreloror/plavix/prasugrel, n (%)

53 (16%)

21 (15%)

0.92

 Statin, n (%)

222 (65%)

84 (61%)

0.36

 CCB, n (%)

60 (18%)

28 (20%)

0.50

 Diuretic, n (%)

105 (31%)

46 (33%)

0.60

ECG/imaging

 ECG Q wave, n (%)

17 (5%)

4 (3%)

0.31

 ECG ST depression, n (%)

19 (6%)

6 (4%)

0.58

 ECG paced, n (%)

19 (6%)

9 (7%)

0.69

 ECG LBBB, n (%)

18 (5%)

13 (9%)

0.09

 ECG atrial fibrillation/atrial flutter, n (%)

31 (9%)

20 (14%)

0.08

 Nuclear EF

59.6 (11.9)

60.4 (12.4)

0.53

 QPS SRS, median (Q1, Q3)

0.5 (0.0, 3.0)

0.0 (0.0, 2.0)

0.20

Clinical Presentation

 Typical symptoms, n (%)

28 (8%)

13 (10%)

0.62

  1. Continuous variables expressed as mean ± standard deviation for symmetric data and median (interquartile range) for asymmetric data. Categorical variables expressed as count and percentage of patients
  2. Abbreviations: CABG coronary artery bypass grafts, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, CRT cardiac resynchronization therapy; ECG electrocardiogram, ICD implantable cardioverter defibrillator, HFpEF heart failure with preserved ejection fraction, HFrEF heart failure with reduced ejection fraction, LBBB left bundle branch block, LVEF left ventricular ejection fraction, NSTEMI non-ST elevation myocardial infarction, OSA obstructive sleep apnea, PCI percutaneous intervention, QPS Quantitative Perfusion SPECT, SRS summed rest score, STEMI ST elevation myocardial infarction
Back to article page